Breast Cancer Profiling Project, Drug Sensitivity phase I: Fixed-cell GR measures of 35 breast cell lines to 34 small molecule perturbagens from library plate I. Dataset 2 of 2: Calculated dose response metrics - Dataset (ID:20344)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Primary Target | Pathway | GR50 | GRmax | GR_AOC | Death_AUC | GR Hill Coefficient | GEC50 | GR r2 |
|---|---|---|---|---|---|---|---|---|---|---|
| HCC1419 | Ceritinib | ALK | RTK | 2.6149 | -0.8670 | 0.2083 | 0.0855 | 2.5745 | 4.0066 | 0.99248 |
| HCC70 | Topotecan | Topo I | Chemotherapy | 0.0094575 | -0.8614 | 1.0593 | 0.2429 | 0.6102 | 0.049603 | 0.96643 |
| T47D | Ceritinib | ALK | RTK | 1.5629 | -0.8550 | 0.3123 | 0.1208 | 1.6029 | 3.1015 | 0.97809 |
| PDX1328 | Cediranib | VEGFR/cKIT | RTK | 0.95412 | -0.8534 | 0.3764 | 0.0972 | 1.1127 | 2.5609 | 0.95134 |
| MDA-MB-361 | INK-128 | mTORC1/2 | PI3K/mTOR | 0.0036192 | -0.8457 | 1.0956 | 0.2779 | 1.1991 | 0.0074773 | 0.98876 |
| MDA-MB-134-VI | Dinaciclib | pan CDK | Cell cycle | 0.010529 | -0.8440 | 0.7452 | 0.1522 | 2.1701 | 0.015963 | 0.99365 |
| MDA-MB-157 | Topotecan | Topo I | Chemotherapy | 0.0059504 | -0.8333 | 1.0843 | 0.2143 | 0.6347 | 0.024255 | 0.91127 |
| HCC70 | Abemaciclib | CDK4/6 | Cell cycle | 1.885 | -0.8264 | 0.2315 | 0.0832 | 2.5102 | 2.8439 | 0.99569 |
| SK-BR-3 | Ceritinib | ALK | RTK | 0.98319 | -0.8254 | 0.3174 | 0.0975 | 1.2454 | 2.3754 | 0.98337 |
| MDA-MB-134-VI | Buparlisib | pan PI3K | PI3K/mTOR | 0.15425 | -0.8251 | 0.6432 | 0.1617 | 0.9833 | 0.45209 | 0.98862 |
| PDX1328 | AZD7762 | CHK1/2 | Cell cycle | 0.035587 | -0.8228 | 0.8326 | 0.1855 | 1.2761 | 0.066257 | 0.96822 |
| MDA-MB-453 | Torin2 | mTOR/ATM/ATR | PI3K/mTOR | 0.0083807 | -0.8141 | 0.6934 | 0.2249 | 0.9084 | 0.023455 | 0.98046 |
| HCC1500 | Cediranib | VEGFR/cKIT | RTK | 3.8594 | -0.8084 | 0.1304 | 0.0735 | 3.4916 | 5.2864 | 0.99235 |
| HCC1500 | Topotecan | Topo I | Chemotherapy | 0.0054632 | -0.8011 | 1.2171 | 0.1857 | 0.7137 | 0.022012 | 0.99509 |
| MDA-MB-361 | Alpelisib | PI3Ka | PI3K/mTOR | 0.22264 | -0.7994 | 0.5323 | 0.1181 | 0.6802 | 1.1196 | 0.97671 |
| MDA-MB-157 | AZD7762 | CHK1/2 | Cell cycle | 0.015418 | -0.7858 | 0.9840 | 0.3122 | 0.8223 | 0.045445 | 0.98837 |
| HCC1419 | Topotecan | Topo I | Chemotherapy | 0.0071886 | -0.7857 | 0.9904 | 0.1711 | 0.4002 | 0.11192 | 0.94532 |
| HCC70 | Doxorubicin | Chemo | Chemotherapy | 0.010621 | -0.7794 | 0.7867 | 0.1459 | 2.0410 | 0.014138 | 0.93856 |
| PDX1328 | Doxorubicin | Chemo | Chemotherapy | 0.013267 | -0.7789 | 0.8023 | 0.1468 | 1.4934 | 0.021574 | 0.96338 |
| MDA-MB-157 | Doxorubicin | Chemo | Chemotherapy | 0.0032329 | -0.7766 | 0.9661 | 0.1885 | 0.9535 | 0.006701 | 0.93404 |
| MDA-MB-134-VI | Luminespib | HSP90 | Misc | 0.0047553 | -0.7660 | 0.9424 | 0.2076 | 3.5318 | 0.006139 | 0.99851 |
| SUM1315MO2 | Ceritinib | ALK | RTK | 0.6688 | -0.7650 | 0.4135 | 0.0975 | 1.0318 | 1.9396 | 0.99439 |
| MDA-MB-453 | Abemaciclib | CDK4/6 | Cell cycle | 0.0057723 | -0.7647 | 0.8495 | 0.1526 | 0.2725 | 0.32512 | 0.73985 |
| MDA-MB-361 | Topotecan | Topo I | Chemotherapy | 0.011361 | -0.7622 | 1.1276 | 0.2239 | 1.9673 | 0.01715 | 0.98983 |
| PDX1328 | Abemaciclib | CDK4/6 | Cell cycle | 0.0036552 | -0.7514 | 0.8680 | 0.0940 | 0.2489 | 0.30192 | 0.79917 |